ABC Proteins and Oncology: Expression, Detection, and Implication of ABC Proteins in Solid Tumors

ABC Transporters and Multidrug Resistance

Volumn , Issue , 2009, Pages 143-176

  Bernaudin, Jean François ^a   Fajac, Anne ^a   Fleury Feith, Jocelyne ^a   Kerrou, Khaldoun ^b   Lacave, Roger ^a  

^a SORBONNE UNIVERSITÉ   (France)

^b HÔPITAL TENON   (France)

Author keywords

ABC proteins and oncology; Anticancer drugs ABC transporter substrates; Host and pharmacogenetics of ABC transporters and solid tumors

Indexed keywords

EID: 84860291355     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470495131.ch5     Document Type: Chapter

References (156)

1. Monti E. 2006. Molecular determinants of intrinsic multidrug resistance in cancer cells and tumors. In Cancer Drug Discovery and Development: Cancer Drug Resistance, Vol. 1., ed. B Teicher, 241-260. Totowa, NJ: Humana Press.
2. Borst P, Jonkers J, and Rottenberg S. 2007. What makes tumors multidrug resistant? Cell Cycle 6: 2782-2787.
3. Schmitt CA. 2003. Senescence, apoptosis and therapy-Cutting the lifelines of cancer. Nat Rev Cancer 2: 286-295.
4. Lage H. 2003. ABC-transporters: Implications on drug resistance from microorganisms to human cancers. Int J Antimicrob Agents 22: 188-199.
5. Sarkadi B, Homolya L, Szakacs G, and Varadi A. 2006. Human multidrug resistance ABCB and ABCG transporters: Participation in a chemoimmunity defense system. Physiol Rev 86: 1179-1236.
6. Higgins CF and Linton KJ. 2003. ABC transporters an introduction and overview. In ABC Transporters, From Bacteria to Man, Vol. 1., ed. BH Holland, SPC Cole, K Kuchler, and CF Higgins, xvii-xxiii. London: Academic Press.
7. Dano K. 1973. Active outward transport of daunomycin in resistant Ehrlich ascites tumor cells. Biochem Biophys Acta 323: 466-483.
8. Sharom FJ. 2008. ABC multidrug transporters: Structure, function and role in chemoresistance. Pharmacogenomics 9: 105-127.
9. Gillet JP, Efferth T, and Remacle J. 2007. Chemotherapy-induced resistance by ATP-binding cassette transporter genes. Biochim Biophys Acta 775: 237-262.
10. Hardwick LJA, Velamakanni S, and van Veen HW. 2007. The emerging pharma-cotherapeutic significance of the breast cancer resistance protein (ABCG2). Br J Pharmacol 151: 163-174.
11. Hegedus T, Orfi L, Seprodi A, Varadi A, Sarkadi B, and Keri G. 2002. Interaction of tyrosine kinase inhibitors with the human multidrug transporter proteins, MDR1 and MRP1. Biochim Biophys Acta 1587: 318-325.
12. Lemos C, Jansen G, and Peters GJ. 2008. Drug transporters: Recent advances concerning BCRP and tyrosine kinase inhibitors. Br J Cancer 98: 857-862.
13. Krause DS and Van Etten RA. 2005. Tyrosine kinases as targets for cancer therapy. New Engl J Med 353: 172-187.
14. Le Tourneau C, Faivre S, and Raymond E. 2008. New developments in multitargeted therapy for patients with solid tumors. Cancer Treat Rev 34: 37-48.
15. Elkind NB, Szentpétery Z, Apáti A, Ozvegy-Laczka C, Várady G, Ujhelly O et al. 2005. Multidrug transporter ABCG2 prevents tumor cell death induced by the epidermal growth factor receptor inhibitor Iressa (ZD1839, Gefitinib). Cancer Res 65: 1770-1777.
16. Declèves X, Bihorel S, Debray M, Yousif S, Camenisch G, and Scherrmann JM. 2008. ABC transporters and the accumulation of imatinib and its active metabolite CGP74588 in rat C6 glioma cells. Pharmacol Res 57: 214-222.
17. Nakanishi T, Shiozawa K, Hassel BA, and Ross DD. 2006. Complex interaction of BCRP/ABCG2 and imatinib in BCR-ABL-expressing cells: BCRP-mediated resistance to imatinib is attenuated by imatinib-induced reduction of BCRP expression. Blood 108: 678-684.
18. Shi Z, Peng XX, Kim IW, Shukla S, Si QS, Robey RW et al. 2007. Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance. Cancer Res 67: 11012-11020.
19. Nagashima S, Soda H, Oka M, Kitazaki T, Shiozawa K, Nakamura Y et al. 2006. BCRP/ABCG2 levels account for the resistance to topoisomerase I inhibitors and reversal effects by gefitinib in non-small cell lung cancer. Cancer Chemother Pharmacol 58: 594-560.
20. Schwab R, Micsik T, Szokolóczi O, Schafer E, Tihanyi B, Tihanyi T et al. 2007. Functional evaluation of multidrug resistance transporter activity in surgical samples of solid tumors. Assay Drug Dev Technol 5: 541-550.
21. Beck WT, Grogan TM, Willman CL, Cordon-Cardo C, Parham DM, Kuttesch JF et al. 1996. Methods to detect P-glycoprotein-associated multidrug resistance in patients' tumors: Consensus recommendations. Cancer Res 56: 3010-3020.
22. Chevillard S, Vielh P, Validire P, Marie JP, Faussat AM, Barbu V et al. 1997. French multicentric evaluation of MDR1 gene expression by RT-PCR in leukemia and solid tumours. Standardization of RT-PCR and preliminary comparisons between RT-PCR and immunohistochemistry in solid tumours. Leukemia 11: 1095-1106.
23. Marie JP, Legrand O, Perrot JY, Chevillard S, Huet S, and Robert J. 1997. Measuring multidrug resistance expression in human malignancies: Elaboration of consensus recommendations. Semin Hematol 34(Suppl. 5): 63-71.
24. Scheffer GL, Kool M, Heijn M, de Haas M, Pijnenborg AC, Wijnholds J et al. 2000. Specific detection of multidrug resistance proteins MRP1, MRP2, MRP3, MRP5, and MDR3 P-glycoprotein with a panel of monoclonal antibodies. Cancer Res 60: 5269-5277.
25. Trock BJ, Leonessa F, and Clarke R. 1997. Multidrug resistance in breast cancer: A meta-analysis of MDRl/gpl70 expression and its possible functional significance. J Natl Cancer Inst 89: 917-931.
26. Bates SE. 2003. Solving the problem of multidrug resistance: ABC transporters in clinical oncology. In ABC Transporters, from Bacteria to Man, Vol. 1, ed. BH Holland, SPC Cole, K Kuchler, and CF Higgins, 359-391. London: Academic Press.
27. Berger W, Setinek U, Hollaus P, Zidek T, Steiner E, Elbling L et al. 2005. Multidrug resistance markers P-glycoprotein, multidrug resistance protein 1, and lung resistance protein in non-small cell lung cancer: Prognostic implications. J Cancer Res Clin Oncol 131: 355-363.
28. Doubre H, Césari D, Mairovitz A, Bénac C, Chantot-Bastaraud S, Dagnon K et al. 2005. Multidrug resistance-associated protein (MRP1) is overexpressed in DNA aneuploid carcinomatous cells in non-small cell lung cancer (NSCLC). Int J Cancer 113: 568-574.
29. Bouhamyia L, Chantot-Bastaraud S, Zaidi S, Roynard P, Prengel C, Bernaudin JF et al. 2007. Immunolocalization and cell expression of lung resistance-related protein (LRP) in normal and tumoral human respiratory cells. J Histochem Cytochem 55: 773-782.
30. Berger W, Elbling L, Hauptmann E, and Micksche M. 1997. Expression of the multidrug resistance-associated protein (MRP) and chemoresistance of human non-small-cell lung cancer cells. Int J Cancer 73: 84-93.
31. Nooter K, Westerman AM, Flens MJ, Zaman GJ, Scheper RJ, van Wingerden KE et al. 1995. Expression of the multidrug resistance-associated protein (MRP) gene in human cancers. Clin Cancer Res 1: 1301-1310.
32. Gambhir SS. 2002. Molecular imaging of cancer with positron emission tomography. Nat Rev Cancer 2: 683-693.
33. Margolis DJ, Hoffman JM, Herfkens RJ, Jeffrey RB, Quon A, and Gambhir SS. 2007. Molecular imaging techniques in body imaging. Radiology 245: 333-356.
34. Sharma V. 2004. Radiopharmaceuticals for assessment of multidrug resistance P-glycoprotein-mediated drug transport activity. Bioconjugate Chem 15: 1464-1474.
35. Piwnica-Worms D, Chiu M, Budding M, Kronauge J, Kramer R, and Croop J. 1995. Functional imaging of multidrug-resistant P-glycoprotein with an organotechne-tium complex. Cancer Res 53: 977-984.
36. Piwnica-Worms D, Rao V, Kronauge J, and Croop J. 1995. Characterization of multidrug-resistance P-glycoprotein transport function with an organotechnetium cation. Biochemistry 34: 12210-12220.
37. Cordobes M, Starzec A, Delmon-Moingeon L, Blanchot C, Kouyoumdjian JC, Prevost G et al. 1996. Technetium-99m-sestamibi uptake by human benign and malignant breast tumor cells: Correlation with mdr gene expression. J Nucl Med 37: 286-289.
38. Crankshaw C, Marmion M, Luker G, Rao V, Dahlheimer J, Burleigh B et al. 1998. Novel Tc(III)-Q-complexes for functional imaging of the multidrug resistance (MDR1) P-glycoprotein. JNucl Med 39: 77-86.
39. Ballinger JR, Bannerman J, Boxen I, Firby P, Hartman NG, and Moore MJ. 1996. Technetium-99m-tetrofosmin as a substrate for P-glycoprotein: In vitro studies in multidrug-resistant breast tumor cells. J Nucl Med 37: 1578-1582.
40. Schneider J, Gonzales-Roces S, Pollan M, Lucas R, Tejerina A, Martin M et al. 2001. Expression of LRP and MDR1 in locally advanced breast cancer predicts axillary node invasion at the time of rescue mastectomy after induction chemotherapy. Breast Cancer Res 3: 183-191.
41. Luker GD, Fracasso PM, Dobkin J, and Piwnica-Worms D. 1997. Modulation of the multigrug resistance P-glycoprotein: Detection withTc-99m-sestamibi in vivo. J Nucl Med 38: 369-372.
42. Del Vecchio S, Ciarmiello A, Potena MI, Carriero MV, Mainolfi C, Botti G et al. 1997. In vivo detection of multidrug resistance (MDR1) phenotype by techne-tium-99-sestamibi scan in untreated breast cancer patients. Eur J Nucl Med 24: 150-159.
43. Sharma V, Luker G, and Piwnica-Worms D. 2002. Molecular imaging of gene expression and protein function in vivo with PET and SPECT. J Magn Reson Imaging 16: 336-351.
44. Gottesman M, Fojo T, and Bates S. 2002. Multidrug resistance in cancer: Role of ATP-depended transporters. Nat Rev Cancer 2: 48-58.
45. Chen C, Meadows B, Regis J, Kalafsky G, Fojo T, Carrasquillo JA, and Bates SE. 1997. Detection of in vivo P-glycoprotein inhibition by PSC 833 using Tc99m-sestamibi. Clin Cancer Res 3: 545-552.
46. Agrawal M, Abraham J, Balis F, Edgerly M, Stein WD, Bates S et al. 2003. Increased Tc-99m-sestamibi accumulation in normal liver and drug resistant tumors after the administration of glycoprotein inhibitor, XR9576. Clin Cancer Res 9: 650-656.
47. Del Vecchio S, Ciarmello A, and Salvatore M. 2000. Scintigraphic detection of multidrug resistance in cancer. Cancer Biother Radiopharm 15: 327-337.
48. Del Vecchio S, Zannetti A, Aloj L, and Salvatore M. 2003. MIBI as prognostic factor in breast cancer. Q J Nucl Med 47: 46-50.
49. Burak Z, Moretti JL, Ersoy O, Sanli U, Kantar M, Tamgac F et al. 2003. Tc-99m-MIBI imaging as a predictor of therapy response in osteosarcoma compared with multidrug resistance-associated and P-glycoprotein expression. J Nucl Med 44: 1394-1401.
50. Shih C, Shiau Y, Wang J, Ho S, and Kao A. 2003. Using technetium-99m tetrofos-min chest imaging to predict taxol-based chemotherapy response in non-small-cell lung cancer but not related to lung resistance protein expression. Lung 181: 103-111.
51. Song HC, Lee JJ, Bom HS, Chung IJ, Kim HJ, Park YK et al. 2003. Double-phase Tc-99m MIBI scintigraphy as a therapeutic predictor in patients with non-Hodgkin's lymphoma. Clin Nucl Med 28: 457-462.
52. Sharma V, Beatty A, Wey SP, Dahlheimer J, Pica C, Crankshaw C et al. 2000. Novel gallium (III) complexes transported by MDR1 P-glycoprotein: Potential PET imaging agents for probing P-glycoprotein-mediated transport activity in vivo. Chem Biol 7: 335-343.
53. Bigott H, McCarthy D, Wust F, Dahlheimer J, Piwnica-Worms D, and Welch M. 2001. Production, processing and uses of 94m-Tc. J Labelled Comp Radiopharm 44: S119-S121.
54. Packard A, Kronauge J, Barbarics E, Kiani S, and Treves S. 2002. Synthesis and biodistribution of a lipophilic 64Cu-. abeled monocationic copper (II) complex. Nucl Med Biol 29: 289-294.
55. Hsueh WA, Kesner AL, Gangloff A, Pegram MD, Beryt M, Czernin J, Silverman DH et al. 2006. Predicting chemotherapy response to paclitaxel with 18F-Fluoropaclitaxel and PET. J Nucl Med 47: 1995-1999.
56. Burger H, Foekens JA, Look MP, Meijer-van Gelder ME, Klinjn JG, Wiemer EA et al. 2003. RNA expression of breast cancer resistance protein, lung resistance-related protein, multidrug resistance-related proteins 1 and 2, and multidrug resistance gene 1 in breast cancer: Correlation with chemotherapeutic response. Clin Cancer Res 9: 827-836.
57. Faneyte IF, Kristel PM, Maliepaard M, Scheper GL, Schellens JH, and van de Vijver MJ. 2002. Expression of the breast cancer resistance protein in breast cancer. Clin Cancer Res 8: 1068-1074.
58. Faneyte IF, Kristel PM, and van de Vijver MJ. 2004. Multidrug resistance associated genes MRP1, MRP2 and MRP3 in primary and anthracycline exposed breast cancer. Anticancer Res 24: 2931-2939.
59. Lacave R, Coulet F, Ricci S, Touboul E, Flahault A, Rateau JG et al. 1998. Comparative evaluation by semiquantitative reverse transcriptase polymerase chain reaction of MDR1, MRP and GSTp gene expression in breast carcinomas. Br J Cancer 77: 694-702.
60. Moureau-Zabotto L, Ricci S, Lefranc JP, Coulet F, Genestie C, Antoine M et al. 2006. Prognostic impact of multidrug resistance gene expression on the management of breast cancer in the context of adjuvant therapy based on a series of 171 patients. Br J Cancer 94: 473-480.
61. Oshishi Y, Oda Y, Uchiumi T, Kobayashi T, Hirakawa T, Miyamoto S et al. 2002. ATP-binding cassette superfamily transporter gene expression in human primary ovarian carcinoma. Clin Cancer Res 8: 3767-3775.
62. Lu L, Katsaros D, Wiley A, Rigault de la Longrais IA, Puopolo M, and Yu H. 2007. Expression of MDR1 in epithelial ovarian cancer and its association with disease progression. Oncol Res 16: 395-403.
63. Young LC, Campling BG, Cole SP, Deeley RG, and Gerlach JH. 2001. Multidrug resistance proteins MRP3, MRP1 and MRP2 in lung cancer: Correlation of protein levels with drug response and messenger RNA levels. Clin Cancer Res 7: 1798-1804.
64. Kawabata S, Oka M, Soda H, Shiozawa K, Nkatomi K, Tsurutani J et al. 2003. Expression and functional analyses of breast cancer resistance protein in lung cancer. Clin Cancer Res 9: 3052-3057.
65. de Cremoux P, Jourdan-Da-Silva N, Couturier J, Tran-Perennou C, Schleiermacher G, Fehlbaum P et al. 2007. Role of chemotherapy resistance genes in outcome of neuroblastoma. Pediatr Blood Cancer 48: 311-317.
66. Haga S, Honoshita E, Ikezaki K, Fuhui M, Scheffer GL, Uchiumi T et al. 2001. I nvolvement of the multidrug resistance protein 3 in drug sensitivity and its expression in human glioma. Jpn J Cancer Res 92: 211-219.
67. Zollner G, Wagner M, Fickert P, Silbert D, Fuchsbichler A, Zatloukal K et al. 2005. Hepatobiliary transporter expression in human hepatocellular carcinoma. Liver Int 25: 367-379.
68. Gillet JP, Efferth T, Steinbach D, Hamels J, de Longueville F, Bertholet V et al. 2004. Microarray-based detection of multidrug resistance in human tumor cells by expression profiling of ATP-binding cassette transporter genes. Cancer Res 64: 8987-8993.
69. Annereau JP, Szakacs G, Tucker CJ, Arciello A, Cardarelli C, Collins J et al. 2004. Analysis of ATP-binding cassette transporter expression in drug-selected cell lines by a microarray dedicated to multidrug resistance. Mol Pharmacol 66: 1397-1401.
70. Tóth K, Vaughan MM, Peress NS, Slocum HK, and Rustum YM. 1996. MDR1 P-glycoprotein is expressed by endothelial cells of newly formed capillaries in human gliomas but is not expressed in the neovasculature of other primary tumors. Am J Pathol 149: 853-858.
71. Tatsuta T, Naito M, Oh-hara T, Sugarawa I, and Tsuruo T. 1992. Functional involvement of P-glycoprotein in blood-brain barrier. J Biol Chem 267: 20383-20391.
72. Bart J, Nagengast WB, Coppes RP, Wegman TD, van der Graaf WT, Groen HJ et al. 2007. Irradiation of rat brain reduces P-glycoprotein expression and function. Br J Cancer 97: 322-326.
73. Bart J, Hollema H, Groen HJ, de Vries EG, Hendrikse NH, Sleijfer DT et al. 2004. The distribution of drug-efflux pumps, P-gp, BCRP, MRP1 and MRP2, in the normal blood-testis barrier and in primary testicular tumours. Eur J Cancer 40: 2064-2070.
74. Petrylak DP, Scher HI, Reuter V, O'Brien JP, and Cordon-Cardo C. 1994. P-glycoprotein expression in primary and metastatic transitional cell carcinoma of the bladder. Ann Oncol 5: 835-840.
75. Tanaka Y, Abe Y, Tsugu A, Tamamiya Y, Akatsuka A, Tsuruo T et al. 1994. Ultrastructural localization of P-glycoprotein on capillary endothelial cells in human gliomas. Virchows Arch 425: 133-138.
76. Tredan O, Galmarini CM, Patel K, and Tannock I. 2007. Drug resistance and the solid tumor microenvironment. J Natl Cancer Inst 99: 1441-1454.
77. Semenza GL. 2003. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 3: 721-732.
78. Bristow RG and Hill RP. 2008. Hypoxia and metabolism. Hypoxia, DNA repair and genetic instability. Nat Rev Cancer 8: 180-192.
79. Comerford KM and Colgan SP. 2004. Assessing oxygen sensitivity of the multidrug resistance (MDR) gene. Methods Enzymol 381: 376-387.
80. Thews O, Gassner B, Kelleher DK, and Gekle M. 2008. Activity of drug efflux transporters in tumor cells under hypoxic conditions. Adv Exp Med Biol 614: 157-164.
81. Thews O, Gassner B, Kelleher DK, Schwerdt G, and Gekle M. 2006. Impact of extracellular acidity on the activity of P-glycoprotein and the cytotoxicity of chemotherapeutic drugs. Neoplasia 8: 143-152.
82. Breedveld P, Pluim D, Cipriani G, Dahlhaus F, van Eijndhoven MA, de Wolf CJ et al. 2007. The effect of low pH on breast cancer resistance protein (ABCG2)-mediated transport of methotrexate, 7-hydroxymethotrexate, methotrexate diglutamate, folic acid, mitoxantrone, topotecan, and resveratrol in in vitro drug transport models. Mol Pharmacol 71: 240-249.
83. Krishnamurthy P, Ross DD, Nakanishi T, Bailey-Dell K, Zhou S, Mercer KE et al. 2004. The stem cell marker BCRP/ABCG2 enhances hypoxic cell survival through interactions with heme. J Biol Chem 279: 24218-24225.
84. Krishnamurthy P and Schuetz JD. 2005. The ABC transporter ABCG2/BCRP: Role in hypoxia-mediated survival. Biometals 8: 349-358.
85. Kim M, Turnquist H, Jackson J, Sgagias M, Yan Y, Gong M et al. 2002. The multidrug resistance transporter ABCG2 (breast cancer resistance protein 1) effluxes Hoechst 33342 and is overexpressed in hematopoietic stem cells. Clin Cancer Res 8: 22-28.
86. Lemos C, Jansen G, and Peters GJ. 2008. Drug transporters: Recent advances concerning BCRP and tyrosine kinase inhibitors. Br J Cancer 98: 857-862.
87. Hirschmann-Jax C, Foster AE, Wulf GG, Nuchtern JG, Jax TW, Gobel U et al. 2004. A distinct "side population" of cells with high drug efflux capacity in human tumor cells. Proc Natl Acad Sci USA 101: 14228-14233.
88. Ho MM, Ng AV, Lam S, and Hung JY. 2007. Side population in human lung cancer cell lines and tumors is enriched with stem-like cancer cells. Cancer Res 67: 4827-4833.
89. Dean M, Fojo T, and Bates S. 2005. Tumour stem cells and drug resistance. Nat Rev Cancer 5: 275-284.
90. Lobo NA, Shimono Y, Qian D, and Clarke MF. 2007. The biology of cancer stem cells. Annu Rev Cell Dev Biol 23: 675-699.
91. Loebinger MR, Giangreco A, Groot KR, Prichard L, Allen K, Simpson C et al. 2008. Squamous cell cancers contain a side population of stem-. ike cells that are made chemosensitive by ABC transporter blockade. Br J Cancer 98: 380-387.
92. Schatton T, Murphy GF, Frank NY, Yamaura K, Waaga-Gasser AM, Gasser M et al. 2008. Identification of cells initiating human melanomas. Nature 451: 345-349.
93. Keshet GI, Goldstein I, Itzhaki O, Cesarkas K, Shenhav L, Yakirevitch A et al. 2008. MDR1 expression identifies human melanoma stem cells. Biochem Biophys Res Commun 368: 930-936.
94. Frank NY, Pendse SS, Lapchak PH, Margaryan A, Shlain D, Doeing C et al. 2003. Regulation of progenitor cell fusion by ABCB5 P-glycoprotein, a novel human ATP-binding cassette transporter. J Biol Chem 278: 47156-47165.
95. Frank NY, Margaryan A, Huang Y, Schatton T, Waaga-Gasser AM, Gasser M et al. 2005. ABCB5-mediated doxorubicin transport and chemoresistance in human malignant melanoma. Cancer Res 65: 4320-4333.
96. Cariati M and Purusotham AD. 2008. Stem cells and breast cancer. Histopathology 52: 99-107.
97. Wright MH, Calcagno AM, Salcido CD, Carlson MD, Ambudkar SV, and Varticovski L. 2008. BRCA1 breast tumors contain distinct CD44+/CD24-and CD133+ cells with cancer stem cell characteristics. Breast Cancer Res 10: R10.
98. Korkaya H and Wicha MS. 2007. Selective targeting of cancer stem cells: A new concept in cancer therapeutics. BioDrugs 21: 299-310.
99. Borst P, van Blitterswijk WJ, Borst J, Tepper AD, and Schinkel AH. 1998. New physiological functions for drug-transporting P-glycoproteins. Drug Resist Updat 1: 337-339.
100. Abele R and Tampé R. 2004. The ABCs of immunology: Structure and function of TAP, the transporter associated with antigen processing. Physiology (Bethesda) 19: 216-224.
101. Meissner M, Reichert TE, Kunkel M, Gooding W, Whiteside TL, Ferrone S et al. 2005. Defects in the human leukocyte antigen class I antigen processing machinery in head and neck squamous cell carcinoma: Association with clinical outcome. Clin Cancer Res 11: 2552-2560.
102. Chen M, Abele R, and Tamp é R. 2004. Functional non-equivalence of ATP-binding cassette signature motifs in the transporter associated with antigen processing (TAP). J Biol Chem 279: 46073-46081.
103. Fowler NL and Frazer IH. 2004. Mutations in TAP genes are common in cervical carcinomas. Gynecol Oncol 92: 914-921.
104. Tao J, Li Y, Liu YQ, Li L, Liu J, Shen X et al. 2008. Expression of transporters associated with antigen processing and human leukocyte antigen class I in malignant melanoma and its association with prognostic factors. Br J Dermatol 158: 88-94.
105. Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmöller J, Johne A et al. 2000. Functional polymorphisms of the human multidrug-resistance gene: Multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 97: 3473-3478.
106. Hitzl M, Drescher S, van der Kuip H, Schäffeler E, Fischer J, Schwab M et al. 2001. The C3435T mutation in the human MDR1 gene is associated with altered efflux on the P-glycoprotein substrate rhodamine 123 from CD56+ natural killer cells. Pharmacogenetics 11: 293-298.
107. Fellay J, Marzolini C, Meaden ER, Back J, Buclin T, Chave JP et al. 2002. Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: A pharmacogenetics study. Lancet 359: 30-36.
108. Tanabe M, Ieri I, Nagata N, Inoue K, Ito S, Kanamori Y et al. 2001. Expression of P-glycoprotein in human placenta: Relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene. J Pharmacol Exp Ther 297: 1137-1143.
109. Vaclavikova R, Nordgard SH, Alnaes GIG, Hubackova M, Kubala E, Kodet R et al. 2008. Single nucleotide polymorphisms in the multidrug resistance gene 1 (ABCB1): Effects on its expression and clinicopathological characteristics in breast cancer patients. Pharmacogenet Genomics 18: 263-273.
110. Nakamura T, Sakaeda T, Horinouchi M, Tamura T, Aoyama N, Shirakawa T et al. 2002. Effect of the mutation C3435T at exon 26 of the MDR1 gene on expression level of MDR1 messenger ribonucleic acid in duodenal enterocytes of healthy Japanese subjects. Clin Pharmacol Ther 71: 297-303.
111. Wang D, Johnson AD, Papp AC, Kroetz DL, and Sadee W. 2005. Multidrug resistance polypeptide 1 (MDR1, ABCB1) variant 3435C>T affects mRNA stability. Pharmacogenet Genomics 15: 693-704.
112. Kimchi-Sarfati C, Oh JM, Kim IW, Sauna ZE, Calcagno AM, Ambudkar SV et al. 2007. A "silent" polymorphism in the MDR1 gene changes substrate specificity. Science 315: 525-528.
113. Henningsson A, Marsh S, Loos WJ, Karlsson MO, Garsa A, Mross K et al. 2005. Association of CYP2C8, CYP3A4 and ABCB1 polymorphisms with the pharmacokinetics of paclitaxel. Clin Cancer Res 11: 8097-8104.
114. Tran A, Jullien V, Alexandre J, Rey E, Rabillon F, Girre V et al. 2006. Pharmacokinetics and toxicity of docetaxel: Role of CYP3A4, MDR1, and GST polymorphisms. Clin Pharmacol Ther 79: 570-580.
115. Lewis LD, Miller AA, Rosner GL, Dowell JE, Valdivieso M, Relling MV et al. 2007. A comparison of the pharmacokinetics and pharmacodynamics of docetaxel between African. American and Caucasian cancer patients: CALGB 9871. Clin Cancer Res 13: 3302-3311.
116. Mathijssen RHJ, Marsh S, Karlsson MO, Xie R, Baker SD, Verweij J et al. 2003. Irinotecan pathway genotype analysis to predict pharmacokinetics. Clin Cancer Res 9: 3246-3253.
117. Bosch TM, Huitema ADR, Doodeman VD, Jansen R, Witteveen E, Smit WM et al. 2006. Pharmacogenetic screening of CYP3A and ABCB1 in relation to population pharmacokinetics of docetaxel. Clin Cancer Res 12: 5786-5793.
118. Han JY, Lim HS, Yoo YK, Shin ES, Park YH, Lee SY et al. 2007. Associations of ABCB1, ABCC2, and ABCG2 polymorphisms with irinotecan-pharmacokinetics and clinical outcome in patients with advanced non-small cell lung cancer. Cancer 110: 138-147.
119. Nakajima M, Fujiki Y, Kyo S, Kanaya T, Nakamura M, Maida Y et al. 2005. Pharmacokinetics of paclitaxel in ovarian cancer patients and genetic polymorphisms of CYP2C8, CYP3A4, and MDR1. J Clin Pharmacol 45: 674-682.
120. Sissung TM, Mross K, Steinberg SM, Behringer D, Figg WD, Sparreboom A et al. 2006. Association of ABCB1 genotype with paclitaxel-mediated peripheral neuropathy and neutropenia. Eur J Cancer 42: 2893-2896.
121. Green H, Soderkvist P, Rosenberg P, Horvath G, and Peterson C. 2006. mdr-1 single nucleotide polymorphism in ovarian cancer tissue: G2677T/A coorelates with response to paclitaxel chemotherapy. Clin Cancer Res 12: 854-859.
122. Kafka A, Sauer G, Jaeger C, Grundmann R, Kreienberg R, Zeillinger R et al. 2003. Polymorphism in C3435T of the MDR-1 gene predicts response to preoperative chemotherapy in locally advanced breast cancer. Int J Oncol 22: 1117-1121.
123. Imai Y, Nakane M, Kage K, Tsukahara S, Ishikawa E, Tsuruo T et al. 2002. C421A polymorphism in the human breast cancer resistance protein gene is associated with low expression of Q141K protein and low-level drug resistance. Mol Cancer Ther 1: 611-616.
124. Kobayashi D, Ieiri I, Hirota T, Takane H, Maegawa S, Kigawa J et al. 2005. Functional assessment of ABCG2 (BCRP) gene polymorphisms to protein expression in human placenta. Drug Metab Dispos 33: 94-101.
125. Sparreboom A, Loos WJ, Burger H, Sissung TM, Verweij J, Figg WD et al. 2005. Effect of ABCG2 genotype on the oral bioavailability of topotecan. Cancer Biol Ther 4: 650-658.
126. Li J, Cusatis G, Brahmer J, Sparreboom A, Robey RW, Bates SA et al. 2007. Association of variant ABCG2 and the pharmacokinetics of epidermal growth factor receptor tyrosine kinase inhibitors in cancer patients. Cancer Biol Ther 6: 432-438.
127. Rudin CM, Liu W, Desai A, Karrison T, Jiang X, Janisch L et al. 2008. Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity. J Clin Oncol 26: 1119-1127.
128. Cusatis G, Gregorc V, Li J, Spreafico A, Ingersoll RG, Verweij J et al. 2006. Pharmacogenetics of ABCG2 and adverse reactions to gefitinib. J Natl Cancer Inst 98: 1739-1742.
129. Wojnowski L, Kulle B, Schirmer M, Schluter G, Schmidt A, Rosenberger A et al. 2005. NAD(P)H oxidase and multidrug resistance protein genetic polymorphisms are associated with doxorubicin-induced cardiotoxicity. Circulation 112: 3754-3762.
130. Fojo T and Coley HM. 2007. The role of efflux pumps in drug-resistant metastatic breast cancer: New insights and treatment strategies. Clin Breast Cancer 7: 749-756.
131. Leonessa F and Clarke R. 2003. ATP binding cassette transporters and drug resistance in breast cancer. Endocr Rel Cancer 10: 43-73.
132. Yoh K, Ishii G, Yokose T, Minegishi Y, Tsuta K, Goto K et al. 2004. Breast cancer resistance protein impacts clinical outcome in platinum-based chemotherapy for advanced non-small cell lung cancer. Clin Cancer Res 10: 1691-1697.
133. Usuda J, Ohira T, Suga Y, Oikawa T, Ichinose S, Inoue T et al. 2007. Breast cancer resistance protein (BCRP) affected acquired resistance to gefitinib in a "never-smoked" female patient with advanced non-small cell lung cancer. Lung Cancer 58: 296-299.
134. Baldini N, Scotlandi K, Barbanti-Bròdano G, Manara MC, Maurici D, Bacci G et al. 1995. Expression of P-glycoprotein in high-grade osteosarcomas in relation to clinical outcome. N Engl J Med 333: 1380-1385.
135. Pinedo HM and Giaccone G. 1995. P-glycoprotein-A marker of cancer-cell behavior. N Engl J Med 333: 1417-1419.
136. Weinstein RS, Jakate SM, Dominguez JM, Lebovitz MD, Koukoulis GK, Kuszak JR et al. 1991. Relationship of the expression of the multidrug resistance gene product (P-glycoprotein) in human colon carcinoma to local tumor aggressiveness and lymph node metastasis. Cancer Res 51: 2720-2726.
137. Filipits M, Haddad V, Schmid K, Huynh A, Dunant A, Andr é F et al. 2007. Multidrug resistance proteins do not predict benefit of adjuvant chemotherapy in patients with completely resected non-small cell lung cancer: International Adjuvant Lung Cancer Trial Biologic Program. Clin Cancer Res 13: 3892-3898.
138. Munoz M, Henderson M, Haber M, and Norris M. 2007. Role of the MRP1/ABCC multidrug transporter protein in cancer. IUBMB Life 59: 752-757.
139. Colone M, Calcabrini A, Toccacieli L, Bozzuto G, Stringaro A, Gentile M et al. 2008. The multidrug transporter P-glycoprotein: A mediator of melanoma invasion? J Invest Dermatol 128: 957-971.
140. Zabierowski SE and Herlyn M. 2008. Learning the ABCs of melanoma-initiating cell. Cancer Cell 13: 185-187.
141. Robert J. 1999. Multidrug resistance in oncology: Diagnostic and therapeutic approaches. Eur J Clin Invest 29: 536-545.
142. Faneyte IF, Kristel PM, and van de Vijver MJ. 2001. Determining MDR1/P-glycoprotein expression in breast cancer. Int J Cancer 93: 114-122.
143. Yang X, Uziely B, Groshen S, Lukas J, Israel V, Russell C et al. 1999. MDR1 gene expression in primary and advanced breast cancer. Lab Invest 79: 271-280.
144. Hegewisch-Becker S, Staib F, Löning T, Pichlmeier U, Kröger N, Reymann A et al. 1998. No evidence of significant activity of the multidrug resistance gene product in primary human breast cancer. Ann Oncol 9: 85-93.
145. Dexter DW, Reddy RK, Geles KG, Bansal S, Myint MA, Rogakto A, Leighton JC et al. 1998. Quantitative reverse transcriptase-polymerase chain reaction measured expression of MDR1 and MRP in primary breast carcinoma. Clin Cancer Res 4: 1533-1542.
146. Wang CS, LaRue H, Fortin A, Gariépy G, and Têtu B. 1997. mdr1 mRNA expression by RT-PCR in patients with primary breast cancer submitted to neoadjuvant therapy. Breast Cancer Res Treat 45: 63-74.
147. Filipits M, Suchomel RW, Dekan G, Haider K, Valdimarsson G, Depisch D et al. 1996. MRP and MDR1 gene expression in primary breast carcinomas. Clin Cancer Res 2: 1231-1237.
148. Chevillard S, Pouillart P, Beldjord C, Asselain B, Beuzeboc P, Magdelénat H et al. 1996. Sequential assessment of multidrug resistance phenotype and measurement of S-phase fraction as predictive markers of breast cancer response to neoadjuvant chemotherapy. Cancer 77: 292-300.
149. Mechetner E, Kyshtoobayeva A, Zonis S, Kim H, Stroup R, Garcia R et al. 1998. Levels of multidrug resistance (MDR1) P-glycoprotein expression by human breast cancer correlate with in vitro resistance to taxol and doxorubicin. Clin Cancer Res 4: 389-398.
150. Honkoop AH, van Diest PJ, de Jong JS, Linn SC, Giaccone G, Hoekman K et al. 1998. Prognostic role of clinical, pathological and biological characteristics in patients with locally advanced breast cancer. Br J Cancer 77: 621-626.
151. Linn SC, Pinedo HM, van Ark-Otte J, van der Valk P, Hoekman K, Honkoop AH et al. 1997. Expression of drug resistance proteins in breast cancer, in relation to chemotherapy. Int J Cancer 71(5): 787-795.
152. Bodey B, Bodey B Jr., Gröger AM, Luck JV, Siegel SE, Taylor CR et al. 1997. Immunocytochemical detection of the p170 multidrug resistance (MDR) and the p53 tumor suppressor gene proteins in human breast cancer cells: Clinical and therapeutical significance. Anticancer Res 17: 1311-1318.
153. Del Vecchio S, Ciarmiello A, Pace L, Potena MI, Carriero MV, Mainolfi C et al. 1997. Fractional retention of technetium-99m-sestamibi as an index of P-glycoprotein expression in untreated breast cancer patients. J Nucl Med 38: 1348-1351.
154. Tolcher AW, Cowan KH, Solomon D, Ognibene F, Goldspiel B, Chang R et al. 1996. Phase I crossover study of paclitaxel with r-verapamil in patients with metastatic breast cancer. J Clin Oncol 14: 1173-1184.
155. Lizard-Nacol S, Genne P, Coudert B, Riedinger JM, Arnal M, Sancy C et al. 1999. MDR1 and thymidylate synthase (TS) gene expressions in advanced breast cancer: Relationships to drug exposure, p53 mutations, and clinical outcome of the patients. Anticancer Res 19: 3575-3581.
156. Arnal M, Franco N, Fargeot P, Riedinger JM, Brunet-Lecomte P, and Lizard-Nacol S. 2000. Enhancement of mdr1 gene expression in normal tissue adjacent to advanced breast cancer. Breast Cancer Res Treat 61: 13-20.